These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Proceedings of the symposium on safety pharmacology, presented during the 3rd EPHAR meeting, Lyon, 6-9 July 2001. European Pharmacological Societies. Fundam Clin Pharmacol; 2002 Apr; 16(2):73-156. PubMed ID: 12102033 [No Abstract] [Full Text] [Related]
4. Proceedings and abstracts from the 4th Annual Safety Pharmacology Society meeting, Covington, Kentucky, USA, September 27-29, 2004. J Pharmacol Toxicol Methods; 2005; 52(1):1-221. PubMed ID: 16299890 [No Abstract] [Full Text] [Related]
5. Safety Pharmacology World Europe 2008--Healthcare Communications' Second Annual Conference. Lakeram M IDrugs; 2009 Jan; 12(1):26-8. PubMed ID: 19127501 [No Abstract] [Full Text] [Related]
6. Safety pharmacology methods and models in an evolving regulatory environment. Pugsley MK; de Korte T; Authier S; Huang H; Accardi MV; Curtis MJ J Pharmacol Toxicol Methods; 2017 Sep; 87():1-6. PubMed ID: 28461240 [TBL] [Abstract][Full Text] [Related]
11. Proceedings of the Annual Meeting of the Knee Society Symposium, September 2010, Rochester, Minnesota, USA and the Knee Society Members Meeting, February 2011, San Diego, California, USA. Pagnano MW Clin Orthop Relat Res; 2012 Jan; 470(1):1-249. PubMed ID: 22329029 [No Abstract] [Full Text] [Related]
12. Proceedings of the Safety Pharmacology Society Meeting. Boston, Massachusetts, USA. J Pharmacol Toxicol Methods; 2011; 64(1):1-110. PubMed ID: 22332240 [No Abstract] [Full Text] [Related]
15. Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development? Holbrook M; Malik M; Shah RR; Valentin JP J Pharmacol Toxicol Methods; 2009; 59(1):21-8. PubMed ID: 18834945 [TBL] [Abstract][Full Text] [Related]
16. American Society for Clinical Pharmacology and Therapeutics. Abstracts of papers. Eighty-ninth Annual Meeting, March 9-11, 1988, San Diego, California. Clin Pharmacol Ther; 1988 Feb; 43(2):123-222. PubMed ID: 3338233 [No Abstract] [Full Text] [Related]
17. The impact of drug-related QT prolongation on FDA regulatory decisions. Park E; Willard J; Bi D; Fiszman M; Kozeli D; Koerner J Int J Cardiol; 2013 Oct; 168(5):4975-6. PubMed ID: 23920061 [No Abstract] [Full Text] [Related]
19. An overview of the safety pharmacology society strategic plan. Pugsley MK; Authier S; Koerner JE; Redfern WS; Markgraf CG; Brabham T; Correll K; Soloviev MV; Botchway A; Engwall M; Traebert M; Valentin JP; Mow TJ; Greiter-Wilke A; Leishman DJ; Vargas HM J Pharmacol Toxicol Methods; 2018; 93():35-45. PubMed ID: 29330132 [TBL] [Abstract][Full Text] [Related]
20. [Prolongation of QT interval and evaluation of safety of drugs]. Li Y; Xu J; Zhang W Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2013 Aug; 30(4):905-8. PubMed ID: 24059079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]